Equity Profile

LMAT

LeMaitre Vascular, Inc.

Health CareHealth Care Equipment$2.3B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

LeMaitre Vascular, Inc. (LMAT) operates in the health care sector, specifically focusing on medical devices for vascular surgery....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

$0.70

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and meet demand in the health care equipment sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LMAT Q2-2026 Earnings Preview

Context

Company Snapshot

LeMaitre Vascular, Inc. (LMAT) operates in the health care sector, specifically focusing on medical devices for vascular surgery. The company is significant as it provides essential equipment and solutions that support cardiovascular health, a growing concern in modern healthcare.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.17%

Avg Stock Reaction

-0.41%

Last Quarter Recap

In Q1-2026, LeMaitre reported an EPS of $0.68, slightly beating expectations. The stock saw a modest increase of 0.42% the following day, indicating a positive market reaction.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, expectations are mixed as analysts await clarity on revenue growth and profitability metrics. Investors are particularly focused on whether the company can maintain its recent EPS performance.

Bull Case

If LeMaitre exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS estimates or provides weak guidance, it could raise concerns about its market position and growth potential.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.70

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's ability to expand its market share and meet demand in the health care equipment sector.

Gross Margin

N/A

Gross margin indicates how efficiently the company is producing its products and managing costs, which is vital for maintaining profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability that investors will closely monitor to assess the company's financial performance.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth will provide insights into the company's market demand and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for LeMaitre to exceed EPS expectations based on its recent performance trends and market demand for vascular products.

Supporting Evidence

LeMaitre has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

Options pricing suggests a significant move, indicating that investors expect volatility which could favor a positive surprise.

Key Risk

If the EPS comes in below $0.65, it could undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether LeMaitre can sustain its growth trajectory amid market challenges.

Bull Confirmed If

An EPS of $0.72 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.65 would raise concerns about profitability and market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±3.08%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±3.1% while LMAT has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.4%

Calls (0)P/C Ratio: 12.00Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If LeMaitre beats expectations, history suggests the stock could rise by around 0.06% on the first day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line, the stock may react cautiously as investors await further commentary on future growth prospects.

Miss

A miss could lead to a decline of approximately 1.80%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's outlook on market demand for vascular products.
3Insights into cost management and operational efficiencies.
4Discussion on competitive pressures and market positioning.
5Any changes to guidance or long-term growth targets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

LeMaitre Vascular, Inc. (LMAT) operates in the health care sector, specifically focusing on medical devices for vascular surgery....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

$0.70

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and meet demand in the health care equipment sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LMAT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.17%

Avg Stock Reaction

-0.41%

Last Quarter Recap

In Q1-2026, LeMaitre reported an EPS of $0.68, slightly beating expectations. The stock saw a modest increase of 0.42% the following day, indicating a positive market reaction.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Bull Case

If LeMaitre exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS estimates or provides weak guidance, it could raise concerns about its market position and growth potential.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.70

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's ability to expand its market share and meet demand in the health care equipment sector.

Gross Margin

N/A

Gross margin indicates how efficiently the company is producing its products and managing costs, which is vital for maintaining profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability that investors will closely monitor to assess the company's financial performance.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth will provide insights into the company's market demand and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for LeMaitre to exceed EPS expectations based on its recent performance trends and market demand for vascular products.

Supporting Evidence

LeMaitre has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

Options pricing suggests a significant move, indicating that investors expect volatility which could favor a positive surprise.

Key Risk

If the EPS comes in below $0.65, it could undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether LeMaitre can sustain its growth trajectory amid market challenges.

Bull Confirmed If

An EPS of $0.72 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.65 would raise concerns about profitability and market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±3.08%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±3.1% while LMAT has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.4%

Calls (0)P/C Ratio: 12.00Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If LeMaitre beats expectations, history suggests the stock could rise by around 0.06% on the first day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line, the stock may react cautiously as investors await further commentary on future growth prospects.

Miss

A miss could lead to a decline of approximately 1.80%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's outlook on market demand for vascular products.
3Insights into cost management and operational efficiencies.
4Discussion on competitive pressures and market positioning.
5Any changes to guidance or long-term growth targets.